Clinical trials: BMD
Breast Neoplasms
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
The primary goal of this 5-year study is to determine whether exemestane alone or in combination with celecoxib decreases breast tissue density in healthy postmenopausal women at high risk for breast cancer.
- Trial name
- NCT00073073
- Testing
- Exemestane, Calcium carbonate, Vitamin D
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Georgetown University
Hypogonadism, Diabetes
Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.
Background: Men≥65 years often produce lower levels of testosterone, meaning there is less testosterone circulating to the tissues of the body.
- Conditions
- Hypogonadism, Diabetes, Sarcopenia, Osteoporosis
- Trial name
- NCT00104572
- Testing
- Androgel (Testosterone Gel), Anastrozole (Aromatase Inhibitor), Calcium Cardone 500mg with vitamin D 400 IU
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Duchenne Muscular Dystrophy
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy.
- Trial name
- NCT04281485
- Testing
- PF-06939926
- Where
- 53 sites in United States, Australia and 13 more
- Volunteers
- 114 people
- Sponsor
- Pfizer
Osteoporosis, Bone Diseases, Metabolic
Patient Activation After DXA Result Notification
There is growing evidence that patients undergoing bone mineral density testing (BMD) often do not take important steps to improve their bone health.
- Trial name
- PAADRN (NCT01507662)
- Testing
- Bone Mineral Density Result Letter and Bone Health Brochure
- Where
- 4 sites in United States, Canada
- Volunteers
- 7,749 people, healthy volunteers welcome
- Sponsor
- Fredric D Wolinsky
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
This is a multi-center, randomized, double-blind, parallel-group study. The FF/VI inhalation powder once daily and VI inhalation powder once daily will be evaluated in subjects with COPD over 156 weeks.
- Trial name
- NCT01957150
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
Postmenopausal Osteoporosis
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
The purpose of this study is to examine, via iliac crest bone biopsies, the mechanism of combined teriparatide and denosumab on the bone of postmenopausal osteoporotic women after 3 months of treatment.
- Trial name
- NCT04026256
- Testing
- Teriparatide, Denosumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Endometriosis, Pain
An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis
This study is designed to see how elagolix works compared to placebo in women with endometriosis and to see the effect, if any, on bone mineral density.
- Trial name
- NCT00619866
- Testing
- Elagolix
- Volunteers
- 155 people
- Sponsor
- AbbVie
Anorexia Nervosa, Osteoporosis
The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa, or disordered eating.
- Trial name
- NCT00759772
- Testing
- Teriparatide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Osteoporotic Fractures, Osteoporosis, Postmenopausal
A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women
This proposed study was designed to investigate the prevalence of a 5-year incident osteoporotic fracture and evaluate the association of a 5-year change of 25-hydroxyvitamin D (25[OH]D)/bone turnover makers/bone mineral density…
- Trial name
- PK-VF (NCT02247011)
- Testing
- Questionaire survey, Bone mineral density examination, Vertebral fracture assessment
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Duchenne Muscular Dystrophy
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24 weeks in subjects diagnosed with Duchenne…
- Trial name
- NCT01396239
- Testing
- AVI-4658 (Eteplirsen)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sarepta Therapeutics, Inc.
HIV Infections, Heart Disease
Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
The hypothesis of this study is that 96 weeks of Rosuvastatin will be safe and effective in decreasing cardiovascular risk and bone loss in the HIV+ population.
- Trial name
- NCT01218802
- Testing
- Rosuvastatin 10 mg. daily for 96 weeks
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- University Hospitals Cleveland Medical Center
Duchenne Muscular Dystrophy
A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)
The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male participants with DMD who have…
- Trial name
- NCT03985878
- Testing
- Eteplirsen
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 15 people
- Sponsor
- Sarepta Therapeutics, Inc.
Osteoporosis
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
Osteoporosis is a condition in which the amount of bone is reduced, the bones are weak, and there is an increased risk for fractures.
- Trial name
- NCT00051558
- Testing
- Teriparatide, Alendronate Sodium
- Where
- 15 sites in United States, Austria and 4 more
- Volunteers
- 428 people
- Sponsor
- Eli Lilly and Company
Duchenne Muscular Dystrophy
Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
This long-term extension study is an open-label, multiple-dose study to evaluate the long-term safety, tolerability, efficacy and PD of vamorolone administered once daily by liquid oral suspension over a Treatment Period of 24…
- Trial name
- NCT03038399
- Testing
- Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 46 people
- Sponsor
- ReveraGen BioPharma, Inc.
Osteoarthritis, Arthritis
Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component
This is a monocentric, prospective, randomized clinical survey to verify if the periprosthetic remodelling brought about either the AMIStem or the Quadra femoral component is equivalent.
- Conditions
- Osteoarthritis, Arthritis, Avascular Necrosis, Fracture of the Femoral Neck or Head
- Trial name
- NCT01285843
- Testing
- Anterior Minimally Invasive Approach (AMIS)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Medacta International SA
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Uterine Cervical Neoplasms
Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer
The treatment of cervical cancer with chemotherapy and radiation will make women post menopausal (no estrogen from the ovaries), if a woman is not already in menopause. Estrogen plays a key role in maintaining bone health.
- Trial name
- NCT00966992
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Washington University School of Medicine
Duchenne Muscular Dystrophy
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Primary Objective The primary objective of the study was to establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects.
- Trial name
- NCT02851797
- Testing
- givinostat
- Where
- 42 sites in United States, Belgium and 9 more
- Volunteers
- 179 people
- Sponsor
- Italfarmaco
Change in Bone Mineral Density, Change in Bone Marrow Fat Content
The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Osteoporosis is a generalised bone disease leading to an increased risk of fractures. The disease is caused partly by environmental and partly by genetic factors.
- Trial name
- NCT00609362
- Testing
- Rosiglitazone
- Where
- Denmark
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Osteopenia, Bone Turnover Markers
Effects of Physical Training on Bone Turnover and Quality of Life in Osteopenic Postmenopausal Women.
The aim of our research was to define both in vivo and in vitro whether and to what extent an high-impact exercise program would affect bone cell turnover and improve the QoL in osteopenic postmenopausal women.
- Conditions
- Osteopenia, Bone Turnover Markers, Quality of Life
- Trial name
- NCT03195517
- Testing
- Physical exercise
- Volunteers
- 33 people
- Sponsor
- University Of Perugia